Eisai Co. Ltd (ESALF PINK) stock market data APIs
$30.062
0(0%)
as of October 29, 2026
Try our APIs with
free plan!
Eisai Co. Ltd Financial Data Overview
Price chart is built with
Anychart
Eisai Co., Ltd. engages in the research, development, manufacture, and sale of pharmaceuticals in Japan. The company operates through pharmaceuticals business and other business segments. It offers Lenvima, a multi-kinase inhibitor which is involved in tumor angiogenesis or tumor malignancy; LEQEMBI, a humanized IgG1 monoclonal antibody against amyloid-beta (Aß) protofibrils; and Dayvigo, a novel small molecule compound. The company also provides prescription drugs; and over-the-counter drugs, as well as focuses on neurology and oncology, and other therapeutic areas. It operates in Europe, the Middle East, Africa, Russia, Oceania, the Americas, China, East Asia, the Global South, and internationally. The company was formerly known as Nihon Eisai Co., Ltd. and changed its name to Eisai Co., Ltd. in 1955. Eisai Co., Ltd. was incorporated in 1941 and is headquartered in Tokyo, Japan.
Prev. Close
30.062
Open
30.062
High
30.062
Low
30.062
52 wk Range
23.4934-33.1184
Market Cap
8 459 M
P/E Ratio
32.9341
Shares Outstanding
282 M
Revenue
857 057 M
EPS
0.4061
Dividends (Yield)
0.0338
Beta
-0.085
* We provide hundreds of fields of fundamental data, including EBITDA, P/E ratio, PEG ratio, trailing P/E, shareholders, insider transactions, technical metrics, dividends, splits, earnings, and more. Check out our Fundamental Data API.
Why to choose EODHD?
Prices start at $19.99
24/7 Live support
Robust, powerful and reliable data
API Simplicity of a few lines of code
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
Get Eisai Co. Ltd data using free add-ons & libraries
Get Eisai Co. Ltd Fundamental Data
Eisai Co. Ltd Fundamental data includes:
- Net Revenue: 857 057 M
- EBITDA: 96 127 M
- Earnings Per Share: 0
- Income Statements
- Balance Sheets
- Cash flows
Plans with Fundamental data
Starting from
$
59.99
/mo.
End-of-day & Earnings data
What’s included:
- Latest Release: 2026-08-03
- EPS/Forecast: 39.33
What’s included:
- End of Day, Intraday and Live APIs
- Splits
- Dividends
Eisai Co. Ltd News
New
New clinical data on lecanemab to be presented at CTAD conference 2026
STOCKHOLM, October 30, 2026 /PRNewswire/ -- BioArctic AB's (publ) (Nasdaq Stockholm: BIOA B) partner Eisai will present new clinical and real-world evidence on lecanemab (Leqembi®) at theClinical Tri...
Eisai to Present New Five-Year Lecanemab Data and Real-World Alzheimer's Disease Research at the 19th Clinical Trials on Alzheimer's Disease (CTAD) Conference
TOKYO, Oct. 29, 2026 /PRNewswire/ -- Eisai Co., Ltd. announced today that it will present new Alzheimer's disease (AD) research at the 19th Clinical Trials on Alzheimer's Disease (CTAD) Conference, ta...
Sales of Leqembi® totaled 32.2 billion yen in the third quarter 2026
STOCKHOLM, October 28, 2026 /PRNewswire/ -- BioArctic AB's (publ) (NASDAQ Stockholm: BIOA B) partner Eisai today published the preliminary global revenue for Leqembi for the third quarter 2026, in con...
Catalyst Watch: Meta earnings, Kroger event, and Black Monday turns 39
[bad day at wall street] franckreporter Welcome to Seeking Alpha's Catalyst Watch - a breakdown of some of next week's actionable events that stand out. Read more about the events that may impact sto...
Get Eisai Co. Ltd fresh news feed via Financial News API
Corporate Events Calendar & News package for
$19.99/mo.
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
- Flexibility: No long-term commitments, just a minimum of one month
- Instant access: Get your API key and instructions within seconds of subscribing
Best Offer
All-In-One
$99.99/mo.
What’s included:
- API Calls per Day: 100 000/day
- API Requests per Min.: 1000/minute
- Type of Usage: Personal use
Data access:
Historical EOD, Fundamental, Real-Time, Intraday, Live (Delayed), Technical & Screener APIs, News Feed, 40 000 Stock Logos and many more. See a full list.